Cheap arthritis drug may keep bypass grafts working longer
NCT ID NCT07569328
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether taking a low dose of colchicine (0.5 mg) every day for two years after coronary artery bypass grafting (CABG) can prevent the new blood vessel grafts from failing. About 622 adults who just had bypass surgery will be randomly assigned to get either colchicine or a placebo pill, on top of standard heart medications. The main goal is to see if colchicine reduces the rate of graft blockage or narrowing, as measured by a CT scan at 24 months.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Colchicine (0.5 mg pill daily)
- What this could lead to
- If it works, this could provide a simple, low-cost way to keep bypass grafts open longer, reducing the need for repeat procedures.
- What could go wrong
- This is a single-center trial that hasn't started recruiting yet. Colchicine can cause digestive issues or muscle pain, and the benefit over standard care is unproven.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 622 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Sep 2026
An estimate. Start dates often move.
- Expected to finish
-
Sep 2029
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Be male or female, aged 18 years or older; 2. Within 3 days after successful isolated coronary artery bypass grafting (CABG); 3. Sign informed consent; Exclusion Criteria: 1. Severe valvular heart disease requiring concomitant or staged valvular surgery; 2. History of non-skin cancer in the past 3 years; 3. Inflammatory bowel disease or chronic diarrhea; 4. Neuromuscular diseases or non-transient creatine kinase levels greater than 3 times the upper limit of the normal range (except those associated with myocardial infarction); 5. Clinically significant non-transient (At least 2 laboratory tests) blood abnormalities (Hemoglobin \<100g/L or hematocrit \< 30% or \> 52% or white blood cell count \< 3×109/L or platelet count \< 100×109/L); 6. Estimated glomerular filtration rate (eGFR) \< 30 mL/min/1.73 m² (based on the CKDEPI formula); 7. Serum alanine aminotransferase and/or aspartate aminotransferase levels greater than 2 times the upper limit of the normal range, accompanied by serum total bilirubin levels greater than 2 times the upper limit of the normal range or severe liver disease with coagulation disorders (INR\>1.5) (except for elevated glutamic oxalacetic transaminase associated with myocardial infarction); 8. Decline in cognitive function due to inability to perform basic activities of daily living independently; 9. Drug or alcohol abuse; 10. Other immunosuppressive therapies already in existence or planned; 11. Other causes require long-term colchicine treatment; 12. History of clear or suspected colchicine allergy; 13. Strong CYP3A4 or P-glycoprotein inhibitors (such as cyclosporine, antiretrovirals, antifungals, erythromycin and clarithromycin) have been used and no other alternative drugs can be used.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CABG are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Beijing Anzhen Hospital
Beijing, Beijing Municipality, 100029, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Pre-Surgery nerve block stop years of chest pain after heart surgery?
- A balloon that coats heart arteries in drug, no stent left behind
- Can a common gout pill shield hearts after stents?
- Can ancient herbs speed up heart surgery recovery?
- Can a neck nerve block calm the Body's inflammatory storm after heart surgery?
- Could a decades-old arthritis drug protect dialysis patients' hearts and veins?